Esperion Therapeutics launched a short-term diuretic strategy for heart failure patients ahead of intravenous escalation. The option is positioned as an interim tool for clinicians and patients seeking an alternative before IV treatment is needed.
published
Esperion Therapeutics launched a short-term diuretic strategy for heart failure patients ahead of intravenous escalation. The option is positioned as an interim tool for clinicians and patients seeking an alternative before IV treatment is needed.
Latest documented BWB result
$TSLA · $SPY market result
Exit $TSLA PDS with a .60 profit per contract - was willing to hold if $SPY closed under the SMA 50 but not with a close above it
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.